Terns Pharmaceuticals, Inc.
TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascuā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$52.95
Price0.00%
$0.00
1Y
Price
Market Cap
$4.770b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-25.0%
5y CAGREarnings
-$96.207m
-8.3%
1y CAGR-18.8%
3y CAGR-19.1%
5y CAGREPS
-$1.03
+8.0%
1y CAGR+14.6%
3y CAGR+14.9%
5y CAGRBook Value
$1.007b
$1.025b
Assets$18.554m
Liabilities$919k
DebtDebt to Assets
0.1%
-
Debt to EBITDAFree Cash Flow
-$82.176m
-17.3%
1y CAGR-19.2%
3y CAGR-18.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company